SCHEMBL6417609

SCHEMBL6417609

CC(C)(CO)NC(=O)c1cnccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.56
LONP1 P36776 1/20 0.50
CNR2 P34972 4/20 0.49
CNR1 P21554 2/20 0.49
RAB9A P51151 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
NPC1 O15118 4/20 0.48
NAPRT Q6XQN6 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
GAA P10253 2/20 0.44
ADORA3 P0DMS8 1/20 0.44
TSHR P16473 1/20 0.44
MC4R P32245 1/20 0.44
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30060524 0.83 KDM4E (0.52) KDM4ELONP1RAB9ASMN1; SMN2NPC1
SCHEMBL2628989 0.83 KDM4E (0.63) KDM4ELONP1RAB9ASMN1; SMN2NPC1
SCHEMBL3653585 0.79 KDM4E (0.58) KDM4ELONP1RAB9ASMN1; SMN2NPC1
SCHEMBL11920720 0.77 KDM4E (0.56) KDM4ELONP1RAB9ASMN1; SMN2NPC1
SCHEMBL13218359 0.77 KDM4E (0.56) KDM4ELONP1RAB9ASMN1; SMN2NPC1
SCHEMBL3658510 0.76 KDM4E (0.55) KDM4ELONP1CNR2RAB9ASMN1; SMN2
SCHEMBL30060547 0.76 KDM4E (0.55) KDM4ELONP1CNR2RAB9ASMN1; SMN2
SCHEMBL18130923 0.76 CNR2 (0.52) CNR2CNR1
SCHEMBL15155205 0.76 KDM4E (0.54) KDM4ERAB9ASMN1; SMN2NPC1NAPRT
SCHEMBL31086775 0.76 NPC1 (0.51) KDM4ELONP1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 US disclosed
CN-1278167-A Amide derivatives SUMITOMO PHARMA (JP) 2000-12-27 CN disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 KDM4E 1808/4885LONP1 397/4885CNR2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.